Table 2 : Risk reclassification table and expected number of events with and without incorporating a new risk
marker into therapeutic management via a risk reclassification strategy.


  Post-Marker Risk  

Pre-Marker Risk Low Risk Intermediate Risk High Risk  

Low Risk, n
Expected # of events if not treated
Expected # of events if treated based on pre-marker risk
Expected # of events if treated based on post-marker risk
1409
3.5
3.5
3.5
52
1.1
1.1
0.8
3
0.2
0.2
0.1
1464
--
--
--

Intermediate Risk, n
Expected # of events if not treated
Expected # of events if treated based on pre-marker risk
Expected # of events if treated based on post-marker risk
190
0.5
0.4
0.5
862
17.4
13.0
13.0
105
7.9
5.9
4.0
1157
--
--
--

High Risk, n
Expected # of events if not treated
Expected # of events if treated based on pre-marker risk
Expected # of events if treated based on post-marker risk
0
0.0
0.0
0.0
176
3.6
1.8
2.7
942
70.8
35.4
35.4
1118
--
--
--
  1599 1090 1050 3739

Estimated 2.5-year event rates by post-marker risk strata: Low Risk–0.25%; Intermediate Risk–2.02%; High Risk–7.52%
Estimated 2.5-year treatment effects (relative risk reduction): Low Risk–0%; Intermediate Risk–25%; High Risk–50%

Brent A. Williams Journal of Medical Statistics and Informatics  2013 1:5DOI : 10.7243/2053-7662-1-5